Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
December 14, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event

BURLINGTON, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
November 22, 2022 08:01 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Announces Pricing of $50 Million Public Offering

BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
November 21, 2022 16:01 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
November 09, 2022 16:05 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure ...
November 02, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
October 26, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
October 10, 2022 09:41 ET | Source: scPharmaceuticals, Inc.

UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 ...
October 10, 2022 08:05 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
October 10, 2022 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 ...